23rd Sep 2013 14:34
Vectura Group plc
Results of the Annual General Meeting held on 23 September 2013
Chippenham, UK, 23 September 2013: Vectura Group plc (LSE: VEC) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed by shareholders.
All resolutions were approved on a poll. The results of the poll are set out below.
Resolution | Total votes for (including discretionary votes)* | % | Total votes against* | % | Total votes cast (excluding votes withheld) | Votes withheld | |
1 | To receive the Report & Accounts | 273,735,919 | 98.97 | 2,861,701 | 1.03 | 276,597,620 | 102 |
2 | To approve the Report on remuneration | 271,054,029 | 98.87 | 3,097,220 | 1.13 | 274,151,249 | 2,446,473 |
3 | To elect Mr Paul Oliver | 270,122,801 | 97.67 | 6,451,537 | 2.33 | 276,574,338 | 23,384 |
4 | To re-elect Dr Chris Blackwell | 274,634,129 | 99.30 | 1,942,709 | 0.70 | 276,576,838 | 20,884 |
5 | To re-elect Mr Neil Warner | 271,834,393 | 98.29 | 4,720,619 | 1.71 | 276,555,012 | 42,710 |
6 | To re-elect Mr Jack Cashman | 268,121,779 | 97.68 | 6,377,808 | 2.32 | 274,499,587 | 2,098,135 |
7 | To re-elect Dr John Brown | 264,842,510 | 96.49 | 9,634,273 | 3.51 | 274,476,783 | 2,120,939 |
8 | To re-appoint Deloitte LLP | 273,706,805 | 99.72 | 767,972 | 0.28 | 274,474,777 | 2,122,945 |
9 | To authorise the Directors to determine auditor's remuneration | 276,578,158 | 100.00 | 12,351 | 0.00 | 276,590,509 | 7,213 |
10 | To authorise the Directors to allot shares | 276,224,770 | 99.88 | 337,445 | 0.12 | 276,562,215 | 35,507 |
11 | To authorise the Directors to allot equity securities | 249,235,869 | 90.98 | 24,722,823 | 9.02 | 273,958,692 | 2,639,030 |
12 | To authorise the Directors' authority to call general meetings | 272,242,255 | 98.45 | 4,298,669 | 1.55 | 276,540,924 | 56,798 |
*NB: The percentage of votes cast for and against excludes withheld votes.
The Company confirms that copies of all resolutions passed at the Annual General Meeting held earlier today, Monday 23 September 2013, will be submitted to the National Storage Mechanism (NSM) at www.hemscott.com/nsm.co and will shortly be available for viewing.
- Ends -
Enquiries:
Vectura Group plc | +44 (0)1249 667700 |
Chris Blackwell, Chief Executive | |
Paul Oliver, Chief Financial Officer | |
Dr Karl Keegan, Corporate Development Director | |
FTI Consulting | +44 (0)20 7831 3113 |
Ben Atwell | |
John Dineen |
Notes to Editors:
About Vectura
Vectura Group plc and its subsidiaries ("Vectura" or the "Group") is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airway-related diseases. This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $30 billion worldwide.
Vectura has seven products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and license agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK) and Tianjin King York Group Company Limited (KingYork).
Vectura seeks to develop certain programmes itself where this will optimize value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.
Related Shares:
VEC.L